WO2013075399A1 - Composé benzo-hétérocyclique à 5 chaînons non saturé ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, composition pharmaceutique et utilisation associée - Google Patents

Composé benzo-hétérocyclique à 5 chaînons non saturé ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, composition pharmaceutique et utilisation associée Download PDF

Info

Publication number
WO2013075399A1
WO2013075399A1 PCT/CN2012/001555 CN2012001555W WO2013075399A1 WO 2013075399 A1 WO2013075399 A1 WO 2013075399A1 CN 2012001555 W CN2012001555 W CN 2012001555W WO 2013075399 A1 WO2013075399 A1 WO 2013075399A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
carboxylic acid
ester
dimethylamine
substituted
Prior art date
Application number
PCT/CN2012/001555
Other languages
English (en)
Chinese (zh)
Inventor
李卓荣
刘宗英
薛司徒
贺晓波
金洁
司书毅
叶伟东
Original Assignee
中国医学科学院医药生物技术研究所
浙江医药股份有限公司新昌制药厂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院医药生物技术研究所, 浙江医药股份有限公司新昌制药厂 filed Critical 中国医学科学院医药生物技术研究所
Publication of WO2013075399A1 publication Critical patent/WO2013075399A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • Osteoporosis is a systemic bone mass characterized by microstructural destruction of bone tissue.
  • osteoporosis caused by medication in HIV, cardiovascular disease and diabetes patients is becoming more and more serious. Osteoporosis and its complications have become a health problem that attracts the attention of the whole society. It is effective to prevent and treat osteoporosis. Drugs and treatments have also become research hotspots worldwide.
  • osteoblasts obs
  • osteoclasts ocs
  • Osteoblast proliferation and differentiation are regulated by a variety of factors, including Bone Morphogenetic Protein-2 (BMP-2), which plays a key role in the differentiation of osteoblasts.
  • BMP-2 also promotes the expression of other osteogenic factors, such as osteoinductive protein (OP), core binding factor al (Cbfal), alkaline phosphatase (ALP), and fatty acid coupling. Protein 4 (fabp4), etc.
  • OP osteoinductive protein
  • Cafal core binding factor al
  • ALP alkaline phosphatase
  • fabricp4 Protein 4
  • BMP-2 not only has a stimulatory differentiation effect on bone tissue-derived cell lines, such as osteoblast precursor cells, ROB-C26 cells, MC3T3-EK osteoblasts, W-20 bone marrow stromal cells, etc.
  • bone tissue-derived cell lines such as osteoblast precursor cells, ROB-C26 cells, MC3T3-EK osteoblasts, W-20 bone marrow stromal cells, etc.
  • non-bone tissue-derived cell lines such as pluripotent fibroblasts C3H10T1/2 and C212 myoblasts, differentiate into osteoblasts, and induce differentiation of osteoblasts and remodeling of young bones in mesenchymal cells.
  • rhBMP-2 Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2, INFUSE® Bone Graft) for its role in promoting bone deposition and repairing long bones
  • the present invention provides a series of benzo five-membered unsaturated heterocyclic compounds having a structure of the formula I or a pharmaceutically acceptable salt thereof, which has an activity of up-regulating the expression of bone morphogenetic protein BMP-2 and can be used for the treatment of osteoporosis.
  • the invention also provides a preparation method of the benzo five-membered unsaturated heterocyclic compound.
  • the present invention also provides the use of the benzo five-membered unsaturated heterocyclic compound in the treatment of osteoporosis and related patients caused by osteoporosis.
  • the present invention also provides a pharmaceutical composition for treating osteoporosis, which comprises the above-mentioned benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the benzo five-membered unsaturated heterocyclic ring of the present invention is a benzothiophene, benzofuran or an anthracene of a substituted 2-position carboxylic acid ester at a different position (3-, 4-, 5-, 6-, 7-) a compound of formula I which is a parent nucleus, a compound having a substituted ester group or a substituted amide group introduced at the 2-position, and a phenyl 5-membered unsaturated heterocyclic ring having an alkyl group, a halogen, an alkoxy group, an amino group, an acyl group Different substituents such as a carboxyl group and an ester group, and the effect of introducing a substituted ester group or a substituted amide group at the 2-position on the up-regulation of BMP-2 activity of the compound.
  • the benzo five-membered unsaturated heterocyclic compound of the present invention has a structure represented by the formula I, wherein the benzene-unsaturated heterocyclic ring may have an alkyl group, a halogen, a decyloxy group, an amino group, an acyl group, a carboxyl group, an ester group or the like.
  • Substituent; thiophene, furan ring or pyrrole moiety is a hydrocarbyl group, a carboxyl group, an acyl group, a decyloxy group, a sulfonic acid group, a phosphoric acid group, a sodium phosphate, a dihydrocarbylamine of 1 to 6 carbons, a morpholine, a piperidine, a N - Ethanylpiperazine, pyrrolidine, hydrocarbyl piperazine of 1 to 6 carbons, decahydropyrido[1,2 - ⁇ ]pyrazine, and the like.
  • the present invention provides a benzo five-membered unsaturated heterocyclic compound having a structure represented by the formula I or a pharmaceutically acceptable salt thereof,
  • X is selected from 0, S or NR 8 , wherein R 8 is selected from any one of H, a hydrocarbyl group, a halogenated hydrocarbyl group, a carbonyl hydrocarbyl group, a hydroxyhydrocarbyl group, an aminohydrocarbyl group, and a hydrocarbyloxy group;
  • Y is selected from 0 or NR!'; wherein R!' is selected from any of H, -OH, a hydrocarbyl group, an acyl group, an alkoxy group, or a sulfonyl group; R 2 is selected from H or a C1-C6 dihydrocarbyl group;
  • n 0-6 positive integer
  • R 3 is selected from the group consisting of an anthracene, a hydrocarbon group, a halogen, an acyl group, a carboxyl group, an amino group, a substituted amino group, a sulfonic acid group, a nitrile group, and an acyl alkoxy group;
  • R 5 , R 6 , and R 7 are each selected from the group consisting of H, a hydrocarbon group, an alkoxy group, a halogen group, a carboxyl group, an amino group, a substituted amino group, an acyl group, an ester group, and a sulfonic acid group;
  • R 5 and R 6 are connected via a carbon, oxygen or nitrogen together, form a 5-7 membered ring structure or a 5-7 membered ring structure with a substituent group R 9, wherein, R 9 is selected from H, alkyl, haloalkyl Any one of a carbonyl hydrocarbon group, a hydroxy hydrocarbon group, an amino hydrocarbon group, and a hydrocarbyloxy group.
  • the hydrocarbon group comprises a C1-C18 linear or branched alkyl group and a cycloalkyl group.
  • the alkoxy group comprises a C1-C18 linear or branched alkoxy group.
  • the acyl group comprises an acyl or aryl acyl group substituted by a linear or branched fluorenyl group of C1-C18.
  • the ester group comprises an ester group or an aryl ester group substituted by a C1-C18 linear or branched fluorenyl group.
  • the acylamino group comprises an acylamino or aryl acylamino group substituted by a C1-C18 linear or branched fluorenyl group.
  • the C1-C18 linear or branched fluorenyl group comprises a C1-C18 linear or branched alkyl group selected from the group consisting of methyl, ethyl, isopropyl, n-propyl, Any of n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, or isohexyl.
  • the cyclodecyl group includes any one of cyclopentane and cyclohexan.
  • the C1-C18 linear or branched alkoxy group includes a methoxy group, an ethoxy group, an isopropoxy group, a n-propoxy group, a n-butoxy group, and an isobutoxy group. Any of a group, a sec-butoxy group, a tert-butoxy group, a n-pentyloxy group, an isopentyloxy group, a n-hexyloxy group, and an isohexyloxy group.
  • the acyl group substituted by a C1-C18 linear or branched fluorenyl group includes a formyl group, an acetyl group, an isopropyl group, a n-propyl group, an allyl group, a cyclopropyl group. Any of an acyl group, an n-butyl acyl group, an isobutyl acyl group, a sec-butyl acyl group, a t-butyl acyl group, a n-pentyl acyl group, an isopentyl acyl group, an n-hexyl acyl group, and an isohexyl acyl group.
  • the aryl acyl group includes any one of a phenyl acyl group and a tolyl acyl group.
  • the ester group substituted by a C1-C18 linear or branched alkyl group includes a formyloxy group, an acetoxy group, an isopropyl acyloxy group, a n-propyl acyloxy group, Allyloxy, cyclopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, iso Any one of a pentyl acyloxy group, a n-hexyl acyloxy group, and an isohexyl acyloxy group.
  • the aryl ester group includes any one of a phenyl acyloxy group and a tolyl acyloxy group.
  • the acylamino group substituted by a C1-C18 linear or branched fluorenyl group includes a methyl amide group, an ethyl amide group, an isopropyl amide group, a propyl propyl amide group, an olefin group.
  • the arylamido group includes any one of a phenylamido group and a tolylamino group.
  • the hydrocarbon group is a C1-C6 linear or branched alkyl group.
  • the hydrocarbon group in the halogenated hydrocarbon group, the carbonyl hydrocarbon group, the hydroxy hydrocarbon group, the amino hydrocarbon group or the alkoxy group is any one of C1 to C6 hydrocarbon groups.
  • the substituent of the substituted amino group is a C2-C6 fluorenyl group.
  • the substituent is selected from a C1-C6 lower fluorenyl group, a lower decyloxy group, Any one of halogen, amino or a combination thereof.
  • the benzo five-membered unsaturated heterocyclic compound includes a substituted benzofuranyl-2-substituted carboxylic acid ester, a substituted benzothienyl-2-substituted carboxylic acid ester, and a substituted hydrazine. Any one of a mercapto-2-substituted carboxylic acid ester, a substituted phenylpropanyl-2-yl substituted amide, and a substituted phenylpropenyl-2-substituted amide.
  • the substituted benzofuranyl group includes a methoxy group, a dimethoxy group, Any one or a combination of a fluorenyl group, a halogen, a carboxyl group, an acetyl group, a sulfonic acid group, a methyl carboxylate, a methylene dioxy group, a diamino group of C1-C18.
  • the substituent in the substituted benzothienyl group includes a methoxysulfonic acid group, a methyl carboxylate, a methylene dioxy group, a substituted methylene dioxy group, a diamino group. Any one or a combination thereof.
  • the substituent in the substituted indenyl group includes any one of a substituted methoxy group, a substituted dimethoxy group, a dimethoxy group, or a combination thereof.
  • the substituent in the substituted phenylpropanyl group includes any one of a methylene dioxy group, a methyl carboxylate or a combination thereof.
  • the substituted phenylpropenyl-2-substituted amide comprises a methylene dioxy group.
  • the substituted carboxylic acid ester comprises a carboxylic acid (diethyl 2,-phosphonate), a carboxylic acid (dimethyl 2,-phosphonate), a carboxylic acid (2,- Dimethylamine) Ethyl ester, carboxylic acid (2,-dimethylamine) propyl ester, carboxylic acid pyrrolidine ethyl ester, carboxylic acid piperidinyl ethyl ester, carboxylic acid morpholine ethyl ester, carboxylic acid (1,1-dimethyl Ethyl-2-dimethylamine) Ethyl ester, carboxylic acid [4,-(2"-hydroxyethyl)]piperazine ethyl ester, carboxylic acid phosphonyl methyl ester, and carboxylic acid phosphonyl ethyl ester or Its combination.
  • the substituted amide comprises carboxylic acid (2,-dimethylamine) ethylamine, carboxylic acid (2,-dimethylamine-N-methyl)ethylamine, carboxylic acid (4) , -phosphonoethylidene methylene benzene) Any one or combination of an amine, a carboxylic acid (4'-phosphono sodium methylene benzene) amine.
  • the benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof comprises the following compounds:
  • the benzo five-membered unsaturated heterocyclic compound having the structure of the formula I of the present invention is preferably improved in water solubility, metabolic stability and therapeutic activity, and has an activity of up-regulating BMP-2 protein expression and promoting bone formation.
  • the activity becomes a novel anti-osteoporosis drug or its lead compound.
  • the benzothiophene/furan or anthraquinone compound of the benzo five-membered unsaturated heterocyclic compound of the present invention or a pharmaceutically acceptable salt thereof has an effect of significantly upregulating the expression activity of bone morphogenetic protein BMP-2, and the anti-osteoporosis effect in vivo
  • the results show that the compounds of the present invention have an effect of improving the symptoms of osteoporosis in SAMP6 mice.
  • Another object of the present invention is to provide a process for the preparation of a benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof, comprising the steps of:
  • Step 1) A substituted benzaldehyde having the structure shown in Formula II, a substituted ethyl acetate having the structure shown in Formula VI, is placed in an aprotic solvent, and an inorganic base is added at 0. After stirring at C-60 ° C, the intermediate III is obtained;
  • Step 2) When Y in the structure of formula I is O, intermediate III is hydrolyzed in an aqueous alkaline solution, and heated under reflux with a substituted hydroxy compound under the action of a dehydrating agent. After completion of the reaction, separation and purification are carried out to obtain a target.
  • Compound IV
  • M is OH or N0 2 ;
  • X is 0, S or NR 8 ;
  • Rj , R 2 , R 3 , , R 5 , R 6 , R 7 , R 8 are as defined in claim 1;
  • R 1() is a mercapto group or a halogen; a hydrocarbyloxy group selected from C1 to C18;
  • the structural formula VI of the substituted ethyl acetate is:
  • Another object of the present invention is to provide a process for the preparation of a benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof, comprising the steps of:
  • Step 1) a substituted benzaldehyde having the structure shown in Formula II, a substituted ethyl acetate having the structure shown in Formula VI, is placed in an aprotic solvent, and an inorganic base is added, at 0 ° C to 60 ° C, Stirring reaction Thereafter, intermediate III is obtained;
  • Step 2) When Y is 'in the structure of formula I, intermediate III is hydrolyzed in an aqueous alkaline solution, heated under reflux with thionyl chloride to form an acid chloride, and then added at 0 ° C. Obtaining a mixture; at room temperature, the mixture is reacted with a substituted amino compound, after completion of the reaction, separation and purification to obtain the target compound V;
  • M is OH or N0 2 ;
  • X is 0, S or NR 8 ;
  • Ri , R 2 , R 3 , , R 5 , R 6 , R 7 , R 8 are as defined in claim 1;
  • R 1Q is fluorenyl or Halogen;
  • R n is selected from a C1-C18 alkoxy group; the substituted ethyl acetate has the structural formula VI:
  • the aprotic solvent is DMF.
  • the inorganic base is anhydrous K 2 C0 3 .
  • the alkaline aqueous solution is an aqueous NaOH solution.
  • the dehydrating agent is any one of DIC, DMAP or a combination thereof.
  • the structure of the substituted hydroxy compound is as shown in Formula VII.
  • the acid binding agent is any one of triethylamine and dichloromethane or a combination thereof.
  • the structure of the substituted amino compound is as shown in Formula VIII.
  • Another object of the present invention is to provide a pharmaceutical composition for anti-osteoporosis, which comprises a therapeutically effective amount of the benzo five-membered unsaturated heterocyclic compound of the present invention or a medicinal use thereof A salt and a pharmaceutically acceptable carrier.
  • the benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof is contained in the pharmaceutical composition in an amount of 0.1 wt.% to 99.5 wt.%, preferably 0.5 wt.% to 95 wt. .%.
  • compositions of the present invention may be in various dosage forms well known in the art, and the dosage form suitable for the present invention is selected from oral preparations, external preparations or injections, preferably oral preparations.
  • Oral preparations are selected from the group consisting of tablets, capsules, granules, pills, powders, pills, syrups, lotions, lotions, effervescent, pastes, emulsions, teas, oral solutions, suspensions (dry suspensions or Suspension) or tea, etc.
  • external preparations are selected from the group consisting of gels, ointments (sticks, ointments or ointments), tinctures, lotions, spreads, plasters, creams, ointments, suppositories, etc.
  • Self-injection (injection) infusion or lyophilized powder needle.
  • the compositions of the present invention can be prepared by formulation techniques well known in the art.
  • composition of the present invention further comprises a pharmaceutically acceptable carrier, and the amount and type of the pharmaceutically acceptable carrier are determined according to factors such as the physical and chemical properties and content of the active ingredient in the composition, the type of the preparation, the formulation technique, and the like. .
  • the pharmaceutically acceptable carriers of the present invention are conventional excipients or adjuvants well known in the art for preparing the above formulations.
  • Excipients or excipients commonly used in oral or topical preparations include, but are not limited to, fillers (diluents), lubricants (glidants or anti-adhesives), dispersants, wetting agents, binders, conditioners, solubilizers , antioxidants, bacteriostatic agents, emulsifiers, disintegrators, etc.
  • Binders such as syrup, gum arabic, gelatin, sorbitol, tragacanth, cellulose and its derivatives (eg microcrystalline cellulose, sodium carboxymethylcellulose, ethylcellulose or hydroxypropylmethylcellulose) ), gelatin paste, starch paddle or polyvinylpyrrolidone; fillers such as lactose, powdered sugar, dextrin, starch and its derivatives, cellulose and its derivatives, inorganic calcium salts (such as calcium sulfate, calcium phosphate) , calcium hydrogen phosphate, precipitated calcium carbonate, etc., sorbitol or glycine; lubricants, such as micronized silica gel, magnesium stearate, talc, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol, etc.; disintegrant , for example, starch and its derivatives (such as sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxyprop
  • a buffer composed of (sodium), sodium citrate, sodium phosphate, and disodium hydrogen phosphate; an emulsifier such as polysorbate-80, sorbitan sorbate, pluronic F-68, lecithin , soy lecithin, etc.; solubilizers, such as Tween-80, bile, glycerin, etc.
  • the active ingredient may be mixed with a pharmaceutically acceptable controlled release carrier according to the preparation requirements thereof, and then prepared according to a preparation method of a controlled release preparation well known in the art, such as adding a retarder coating or an active agent.
  • a preparation method of a controlled release preparation well known in the art, such as adding a retarder coating or an active agent.
  • the pellet is prepared into a pellet, such as a sustained-release pellet or a controlled-release pellet;
  • the sustained-release carrier includes, but is not limited to, an oil-based admixture, a hydrophilic colloid or a coating retarder.
  • the oleaginous incorporation agent is selected from any one or a combination of glyceryl monostearate, hydrogenated castor oil, mineral oil, polysiloxane or dimethyl siloxane; Any one or combination of sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, PVP, gum arabic, scutellaria or carbopol; the coating resistance
  • the retardant is selected from the group consisting of ethyl cellulose (EC), hydroxypropylmethyl cellulose (HMPC), polyvinylpyrrolidone (PVP), cellulose acetate phthalate (CAP), acrylic resin, and the like. Or a combination thereof.
  • the pharmaceutical composition is prepared in the form of a tablet, a suspension, a capsule, a granule, a pill, a powder, a pill, a syrup, a mixture, a lotion, an effervescent, and a paste.
  • Agent emulsion, tea, powder, injection (injection), infusion, gel, plaster, plaster, cream, ointment, tincture, lotion, suppository, smear, ointment, ointment .
  • Another object of the present invention is to provide the use of the benzo five-membered unsaturated heterocyclic compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the preparation of a medicament for treating osteoporosis.
  • Example 20 6-carboxylic acid methyl ester benzofuran-2 -carboxylic acid (dimethyl 2,-phosphonate) ethyl ester
  • 2-hydroxy-4-carboxylic acid methyl ester benzaldehyde (1.80 g, 10 mmol) and anhydrous K 2 C0 under ice bath 3 (1.66 g, 12 mmol) was dissolved in DMF (25 ml). After the dropwise addition was completed, the mixture was stirred at 0 ° C for 30 min, and then reacted in an oil bath at 60 ° C for 12 h.
  • N,N-dimethylpropanolamine was used as a raw material and reacted according to the preparation method described in Example 20 to obtain 6-carboxylic acid methyl ester benzofuran-2-carboxylic acid (2'-dimethylamine) propyl ester. (Yield 47%).
  • the morpholinoethanol was used as a raw material and reacted according to the preparation method described in Example 20 to give 6-carboxylic acid methyl ester benzofuran-2-carboxylic acid morpholine ethyl ester (yield: 55%).
  • Example 26 6-carboxylic acid methyl ester benzofuran-2-carboxylic acid (1,1, -Dimethyl-2-dimethylamine)ethyl ester (Compound 26) was reacted with (1,1 '-dimethyl-2-dimethylamine) ethanol as a starting material according to the preparation method described in Example 20 to obtain Methyl 6-carboxylate benzofuran-2-carboxylic acid (1,1,-dimethyl-2-dimethylamine) ethyl ester (yield 37%).
  • Example 27 6-Carboxylic acid methyl ester benzofuran-2-carboxylic acid [4,-(2"-hydroxyethyl) 1 piperazinyl ester (Compound 27) with [4'-(2"-hydroxyl The piperazine ethanol was used as a raw material and reacted according to the preparation method described in Example 20 to obtain 6-carboxylic acid methyl ester benzofuran-2-carboxylic acid [4,-(2"-hydroxyethyl)]piperazine. Ethyl ester (yield 41%).
  • Example 29 5,6-Methylenedioxybenzofuran- 2-carboxylic acid (dimethyl 2,-phosphonate) ethyl ester (compound 29) was reacted with dimethyl 2-hydroxyethylphosphonate according to the preparation method described in Example 28 to give 5,6- Methylene dioxybenzofuran-2-carboxylic acid (dimethyl 2,-phosphonate) ethyl ester (yield 45%).
  • Example 30 5,6-Methylenedioxybenzofuran-2 -carboxylic acid (2,-dimethylamine) ethyl ester (compound 30) The reaction was carried out according to the preparation method described in Example 28 using N,N-dimethylethanolamine as a starting material to obtain 5,6-methylenedioxybenzofuran-2-carboxylic acid (2,-dimethylamine). Ester (yield 50%).
  • the compound 2 was used as a raw material, and then reacted according to the preparation method of Example 42 to give 6-methoxybenzofuran-2-carboxylic acid phosphonic acid ethyl ester (yield: 79%).
  • Example 44 6- Methyl carboxylate benzothiophene-2-carboxylic acid (diethyl 2,-phosphonate) methyl ester (compound 44) 2-nitro-4-carboxylic acid methyl ester benzaldehyde (2.00) under ice bath g, 9.56 mmol) and anhydrous K 2 CO 3 (1.50 g, 11.4 mmol) were dissolved in DMF (25 ml), and ethyl acetate (1.15 g, 9.56 mmol) was slowly added dropwise o 0 ° C Stir for 30 min, then react in a 60 ° C oil bath for 10 h.
  • Example 53 5,6-Methylenedioxybenzothiophene-2- Carboxylic acid (dimethyl 2,-phosphonate) Ethyl ester (Compound 53) Using dimethyl 2-hydroxyethylphosphonate as a starting material, the reaction was carried out in the same manner as in Example 52 to give 5,6-methylenedioxy Benzothiophene-2-carboxylic acid (dimethyl 2'-phosphonate) ethyl ester (yield 51%).
  • Example 56 5,6-methylene Dioxybenzothiophene-2-carboxylic acid [4,-(2"-hydroxyethyl)]piperazine ethyl ester (Compound 56) Using [4,-(2"-hydroxyethyl)]piperazineethanol as a starting material, the reaction of Example 52 gave 5,6-methylenedioxybenzothiophene-2-carboxylic acid [4,- (2"-Hydroxyethyl)]piperazine ethyl ester (yield 39%).
  • the morpholine ethyl ester was used as a starting material, and the mixture was subjected to the procedure of Example 52 to give 5,6-methylenedioxybenzothiophene-2-carboxylic acid morpholine ethyl ester (yield: 54%).
  • N-methyl-5,6-dimethoxy-indole-2-carboxylic acid and morpholinoethanol were used as raw materials, and reacted according to the method of Example 64 to obtain N-methyl-5,6-dimethoxy.
  • the base-B was introduced to the quinone-2-carboxylic acid morpholine ethyl ester (yield: 82%).
  • Example 68 N- (2,- Hydroxyethyl)-5-methoxy-indole-2-carboxylic acid (2,-dimethylamine) ethyl ester (compound 68) with N-(2'-hydroxyethyl)-5-methoxy-
  • the indole-2-carboxylic acid was used as a starting material, which was reacted according to the procedure of Example 64 to give N-(2,-hydroxyethyl)-5-methoxy-indole-2-carboxylic acid (2,-dimethylamine). Ethyl ester (yield 80%).
  • Example 69 N-(2,-methoxy)-6-methoxy-indole-2-carboxylic acid (2,-dimethylamine) ethyl ester (Compound 69) with N-(2'-A The oxy)-6-methoxy-indole-2-carboxylic acid was used as a starting material, which was reacted according to the procedure of Example 64 to give N-(2,-methoxy)-6-methoxy-indole-2. - Carboxylic acid (2,-dimethylamine) ethyl ester (yield 80%).
  • N-carboxymethyl-5-methoxy-indole-2-carboxylic acid was used as a starting material, and then reacted according to the method of Example 64 to give N-carboxymethyl-5-methoxy-indole.
  • Carboxylic acid (2,-dimethylamine) ethyl ester yield 69%).
  • Example 71 5,6-Methylenedioxyphenylpropan-2-carboxylate (2,-dimethylamine) Ethylamine (Compound 71)
  • 2-Hydroxy-4,5-methylenedioxybenzaldehyde (3.32 g, 20 mmol) and anhydrous K 2 CO 3 (3.20 g, 24 mmol) were dissolved in DMF (50 ml), and bromoacetic acid B was slowly added dropwise. Ester (3.34 g, 20 mmol). After the dropwise addition was completed, the mixture was stirred at 0 ° C for 30 min, and then reacted in an oil bath at 60 ° C for 14 h.
  • reaction mixture was poured into ice water, filtered, and chloroform dissolved solid, dried over anhydrous Na 2 S0 4 , filtered, and evaporated to dryness. After silica gel column chromatography, to obtain a yellow solid 4.00 g (86%).
  • the compound 75 was used as a raw material, and reacted according to the method of Example 42 to obtain 5,6-methylenedioxybenzene.
  • Example 86 6-Carboxylic acid methyl ester benzofuran-2-carboxylic acid phosphonium ethyl ester (Compound 86) The compound 21 was used as a starting material and reacted according to the method of Example 42 to give methyl 6-carboxylate benzofuran. 2-carboxylic acid phosphonoethyl ester (yield 79%).
  • the compound 44 was used as a starting material to give 6-carboxylic acid methyl ester benzothiophene-2-carboxylic acid phosphonomethyl ester (yield: 41%).
  • the compound of the present invention can be synthesized stably and reproducibly.
  • Experiment 1 In vitro BMP-2 up-regulation activity screening
  • a screening model for up-regulating BMP-2 was constructed, and plasmid PYJ was transiently transfected into MC3T3E1 cells.
  • the specific process was as follows: 100 ⁇ 7 wells of MC3T3E1 cells were cultured in 96-well sterile plastic culture plates for 8 h. Dilute the appropriate amount of PYJ plasmid DNA in a sterile centrifuge tube with 25 ⁇ 7-well serum-free and anti-anti-DMEM medium. Dilute 0.5 ⁇ ! 7-well LF2000 in 25 ⁇ 7-well serum-free, anti-double-antibody DMEM medium in another sterile centrifuge tube.
  • Reagent within 5 mm, combine the above two tubes, incubate for 20 min at room temperature, add the mixed transfection suspension to the above 96-well plate, mix well with each well 50 and then 96-well plate Placed in a 37 ° C carbon dioxide incubator, culture for a certain period of time and then add appropriate concentration of drug-acting cells before fluorescence detection;
  • the measurement procedure was as follows: Discard the medium in the 96-well plate, gently rinse the cells with 200 PBS (pH 7.0), completely discard the PBS, add 25 ⁇ 7-well l xPLB, shake at room temperature for 15 min, and allow the cells to Completely lysate, completely aspirate the lysate into the corresponding well of a 96-well white plate for fluorescence analysis, and add 70 ⁇ 7-well analysis reagent LARII to the analysis white plate, immediately (within 5 min), place the analysis whiteboard on the Galaxy spectrophotometer.
  • the detection conditions are: no excitation light wavelength, emission light wavelength is empty, Positioning delay is 1.0, Number of intervals 1, Interval time is 1.0s, the shaking mode is set before the instrument reading, and the shaking diameter is 1 mm.
  • the up-regulation rate of the sample was calculated using the set positive control, blank control, and associated data and calculation formulas. The results are shown in Table 1.
  • Up-regulation rate (sample luminescence - DMSO luminescence) / DMSO luminescence xl00%
  • the present invention uses the above BMP-2 screening model to study the up-regulation rate of the compound of formula I of the present invention on BMP-2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé benzo-hétérocyclique à 5 chaînons non saturé présentant la structure de formule générale I ou ses sels pharmaceutiquement acceptables, et un procédé de préparation, une composition pharmaceutique et son utilisation. Des expériences ont montré que le composé de la présente invention a pour effet de surréguler l'activité d'expression de la protéine morphogénétique osseuse BMP-2 et l'anti-ostéoporose in vivo, et a également pour effet d'améliorer les symptômes de l'ostéoporose chez les souris SAMP6. Des tests d'activité in vitro ont montré que le composé de la présente invention présente un effet évident de surrégulation sur la protéine morphogénétique osseuse BMP-2.
PCT/CN2012/001555 2011-11-23 2012-11-19 Composé benzo-hétérocyclique à 5 chaînons non saturé ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, composition pharmaceutique et utilisation associée WO2013075399A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110376491.6 2011-11-23
CN201110376491.6A CN103130705B (zh) 2011-11-23 2011-11-23 苯并五元不饱和杂环类化合物或其药用盐及其制备方法、药物组合物及其应用

Publications (1)

Publication Number Publication Date
WO2013075399A1 true WO2013075399A1 (fr) 2013-05-30

Family

ID=48469044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/001555 WO2013075399A1 (fr) 2011-11-23 2012-11-19 Composé benzo-hétérocyclique à 5 chaînons non saturé ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, composition pharmaceutique et utilisation associée

Country Status (2)

Country Link
CN (1) CN103130705B (fr)
WO (1) WO2013075399A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111196823A (zh) * 2020-03-10 2020-05-26 郑州大学 一种3-膦酰化苯并噻吩类化合物及制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3110932B1 (fr) * 2014-02-25 2019-09-04 Ecolab USA Inc. Nettoyant sanitaire
KR101761682B1 (ko) * 2015-10-07 2017-07-31 한국화학연구원 신규한 인돌-2-카르복실레이트 유도체 및 이를 유효성분으로 포함하는 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1807411A (zh) * 2006-02-20 2006-07-26 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp－2表达活性的五元不饱和杂环化合物
WO2008002674A2 (fr) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Compositions bicycliques et procédés de modulation d'une cascade de kinases
CN101906093A (zh) * 2009-06-05 2010-12-08 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857383A (en) * 1956-03-29 1958-10-21 Searle & Co Amino esters of thianaphthenealkanoic acids
NL277744A (fr) * 1961-05-19
WO2009146182A1 (fr) * 2008-04-18 2009-12-03 Smithkline Beecham Corporation Antagonistes de trpv4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1807411A (zh) * 2006-02-20 2006-07-26 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp－2表达活性的五元不饱和杂环化合物
WO2008002674A2 (fr) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Compositions bicycliques et procédés de modulation d'une cascade de kinases
CN101906093A (zh) * 2009-06-05 2010-12-08 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUO, HUIFANG ET AL.: "Substituted benzothiophene or benzofuran derivatives as a novel class of bone morphogenetic protein-2 up-regulators: synthesis, structure-activity relationships, and preventive bone loss efficacies in senescence accelerated mice (SAMP6) and ovariectomized ats", J. MED. CHEM., vol. 53, 2010, pages 1819 - 1829, XP055010758, DOI: doi:10.1021/jm901685n *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111196823A (zh) * 2020-03-10 2020-05-26 郑州大学 一种3-膦酰化苯并噻吩类化合物及制备方法

Also Published As

Publication number Publication date
CN103130705B (zh) 2016-04-20
CN103130705A (zh) 2013-06-05

Similar Documents

Publication Publication Date Title
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
TWI718113B (zh) 吡啶甲醯胺類衍生物、其製備方法及其在醫藥上的應用
RU2580320C2 (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
TWI617546B (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
CN110099900B (zh) 针对Smoothened突变株的刺猬通路抑制剂
HU230123B1 (hu) Szubsztituált indolil-oxo-acetil-piperazinszármazékok, ezeket tartalmazó készítmények és vírusellenes alkalmazásuk
CN104059039A (zh) 具有gpr40受体功能调节作用的稠环化合物
WO2016192560A1 (fr) Promédicament ténofovir monobenzyl ester phosphamide, procédé de préparation et utilisation de ce dernier
CN115353508B (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN110092740A (zh) 一种稠环化合物及其应用
WO2013075399A1 (fr) Composé benzo-hétérocyclique à 5 chaînons non saturé ou ses sels pharmaceutiquement acceptables, procédé de préparation associé, composition pharmaceutique et utilisation associée
WO2022268066A1 (fr) Agent de dégradation de protéine
HUT62576A (en) Process for producing substituted imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising such compounds
CN115304583A (zh) 靶向抑制clk2的5-吡啶-1h-吲唑类化合物及其应用
JPS60161970A (ja) ジベンズアゼピン‐６‐オン化合物
CN111196801A (zh) 阿朴菲类生物碱衍生物及其制备方法与用途
CN115768751A (zh) 新型甲状腺激素β受体激动剂
JP2020534265A (ja) ４−硫黄置換ポドフィロトキシン系誘導体、その製造方法及び使用
CN112876442A (zh) 一种抗骨质疏松的金合欢素衍生物及其制备方法
JP2019531353A (ja) 重水素化化合物及びその医薬的用途
WO2016026372A1 (fr) Dérivés thiénohétérocycliques ou thiénocycloalkyliques, procédé de préparation de ceux-ci et utilisation de ceux-ci en médecine
CN109265471B (zh) Fxr受体激动剂
CN110981937A (zh) Odn或衍生物的多肽偶合物及其制备方法和应用
CN114276388A (zh) 一种二茂铁哌嗪酰胺类化合物及其制备方法与应用
CN111620816A (zh) 螺桨烷类衍生物、其制备方法、药物组合物和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12851606

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12851606

Country of ref document: EP

Kind code of ref document: A1